Cargando…

mTOR, metabolism, and the immune response in HPV-positive head and neck squamous cell cancer

Extensive preclinical studies have identified mammalian target of rapamycin (mTOR) activation as a frequent molecular signature underlying head and neck squamous cell carcinoma (HNSCC), including the distinct clinical subtype that is human papillomavirus (HPV) related, and have demonstrated the pote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coppock, Joseph D., Lee, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	KeAi Publishing 2016
Materias:	Novel discoveries/Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698505/ https://www.ncbi.nlm.nih.gov/pubmed/29204551 http://dx.doi.org/10.1016/j.wjorl.2016.05.010

Ejemplares similares

Interleukin-6 role in head and neck squamous cell carcinoma progression
por: Choudhary, Moaz M., et al.
Publicado: (2016)

Novel p53 therapies for head and neck cancer
por: Castellanos, Mario R., et al.
Publicado: (2016)

The current status of oncolytic viral therapy for head and neck cancer
por: Old, Matthew O., et al.
Publicado: (2016)

Intra-tumor heterogeneity in head and neck cancer and its clinical implications
por: Mroz, Edmund A., et al.
Publicado: (2016)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
por: Jimeno, A, et al.
Publicado: (2007)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC
por: Coppock, Joseph D., et al.
Publicado: (2016)

mTOR Signalling in Head and Neck Cancer: Heads Up
por: Tan, Fiona H., et al.
Publicado: (2019)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
por: Scheller, T, et al.
Publicado: (2015)

Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome
por: Di Domenico, Fabio, et al.
Publicado: (2019)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
por: Zuo, M, et al.
Publicado: (2015)

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models
por: Ekshyyan, Oleksandr, et al.
Publicado: (2013)

PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications
por: Aguayo, Francisco, et al.
Publicado: (2023)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death
por: Makhov, P, et al.
Publicado: (2014)

mTOR co-targeting strategies for head and neck cancer therapy
por: Wang, Zhiyong, et al.
Publicado: (2017)

Radiosensitization approaches for HPV‐positive and HPV‐negative head and neck squamous carcinomas
por: Dok, Rüveyda, et al.
Publicado: (2019)

The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma
por: Zhou, Chumin, et al.
Publicado: (2020)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway
por: Liu, Weiwei, et al.
Publicado: (2017)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma
por: Wu, Qingqing, et al.
Publicado: (2022)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling
por: Zheng, Anyuan, et al.
Publicado: (2019)

Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma
por: Chou, Ming-Huei, et al.
Publicado: (2021)

SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling
por: Barzegar, Mansoureh, et al.
Publicado: (2017)

Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma
por: Oguejiofor, K, et al.
Publicado: (2015)

p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer
por: de Kort, W. W. B., et al.
Publicado: (2023)

Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
por: García-Carracedo, Darío, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0usdnbmvc65ffnjr5ua77klel7